Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
Public ClinicalTrials.gov record NCT03283371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.
Study identification
- NCT ID
- NCT03283371
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 67 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2018 (Actual)
- Primary completion
- Jan 11, 2020 (Actual)
- Completion
- Nov 18, 2020 (Actual)
- Last update posted
- Dec 14, 2021
2018 – 2020
United States locations
- U.S. sites
- 31
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | — |
| Research Site | Phoenix | Arizona | 85004 | — |
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | San Diego | California | 92103 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Washington D.C. | District of Columbia | 20037 | — |
| Research Site | Jacksonville | Florida | 32209 | — |
| Research Site | Maitland | Florida | 32751 | — |
| Research Site | Orlando | Florida | 32803 | — |
| Research Site | Tallahassee | Florida | 32308 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Honolulu | Hawaii | 96817 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Bethesda | Maryland | 20817 | — |
| Research Site | Chevy Chase | Maryland | 20815 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Saginaw | Michigan | 48602 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Camden | New Jersey | 08103 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | The Bronx | New York | 10467 | — |
| Research Site | Asheville | North Carolina | 28806 | — |
| Research Site | Chapel Hill | North Carolina | 27514 | — |
| Research Site | Durham | North Carolina | 27705 | — |
| Research Site | Akron | Ohio | 44320 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Renton | Washington | 98055 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03283371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2021 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03283371 live on ClinicalTrials.gov.